BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

Two years in, the Hong Kong stock exchange’s biotech chapter is no longer an experiment, but a maturing equity market with all the hallmarks to suggest it can sustainably support innovative companies -- as long...
BC Extra | Dec 6, 2019
Preclinical News

Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

Merck, Codexis design efficient synthesis of Phase II HIV therapy  Merck & Co. Inc. (NYSE:MRK) and Codexis Inc. (NASDAQ:CDXS) researchers designed a way to synthesize HIV therapy islatravir (MK-8591) via a three-step biocatalytic cascade in...
BC Innovations | Nov 21, 2019
Distillery Therapeutics

The flavonoid prunin could treat enterovirus A71 infection

DISEASE CATEGORY: Infectious disease INDICATION: Enterovirus The plant pigment prunin could treat infections by enterovirus A71 strains that cause hand, foot and mouth disease, in which a subset of patients develop paralysis. In cell-based infection...
BC Extra | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

A*STAR spinout Lucence raises $20M  IHH led a $20 million series A round for Lucence, a blood-based cancer diagnostics company spun out of Singapore’s Agency for Science, Technology and Research (A*STAR) in 2016. The company...
BC Innovations | Nov 18, 2019
Distillery Therapeutics

Tyrosine kinase inhibitors for the treatment of pemphigus

DISEASE CATEGORY: Autoimmune disease INDICATION: Pemphigus Tyrosine kinase inhibitors including the dual BCR-ABL/c-Kit inhibitor imatinib could treat pemphigus, an autoimmune blistering disorder. Pemphigus is caused by antibodies against the keratinocyte adhesion molecule DSG3. Imatinib reduced...
BC Innovations | Sep 19, 2019
Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 2Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
BC Innovations | Aug 29, 2019
Distillery Techniques

STAT3-based gene signature to predict response to glioblastoma targeted therapy

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling A STAT3-based gene expression signature could identify glioblastoma multiforme (GBM) patients that will respond to STAT3 inhibitors as monotherapies or in combination with IGF1R (insulin-like growth factor-1 receptor; CD221)...
BC Extra | Jul 12, 2019
Financial News

July 11 Financial Quick Takes: Illumina tumbles on revenue miss; plus PureTech, Horizon and more

Illumina falls after revenue miss  Illumina Inc. (NASDAQ:ILMN) was off $58.66 (16%) to $305 in after-hours trading after reporting preliminary 2Q19 revenues of $835 million, barely topping its $830 million revenues in the prior year’s...
BC Extra | Jun 14, 2019
Preclinical News

June 13 Preclinical Quick Takes: A*STAR's mAb against tumor-displayed antigen; plus Columbia, Genentech and more

A*STAR targets externalized antigen to kill tumor cells   The Agency for Science Technology and Research has licensed PTP4A3-targeting cancer therapy PRL3-zumab to spinout company Intra-Immu SG Pte Ltd. (Singapore). A*STAR and colleagues reported in...
BC Innovations | May 20, 2019
Distillery Therapeutics

MAT2A identified as a target in solid and liquid cancers

DISEASE CATEGORY: Cancer INDICATION: Lung; leukemia; lymphoma; solid tumors Cell and mouse studies suggest inhibiting MAT2A could help treat lung and other solid and liquid cancers. In a panel of human cancer cell lines, including...
Items per page:
1 - 10 of 155
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

Two years in, the Hong Kong stock exchange’s biotech chapter is no longer an experiment, but a maturing equity market with all the hallmarks to suggest it can sustainably support innovative companies -- as long...
BC Extra | Dec 6, 2019
Preclinical News

Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

Merck, Codexis design efficient synthesis of Phase II HIV therapy  Merck & Co. Inc. (NYSE:MRK) and Codexis Inc. (NASDAQ:CDXS) researchers designed a way to synthesize HIV therapy islatravir (MK-8591) via a three-step biocatalytic cascade in...
BC Innovations | Nov 21, 2019
Distillery Therapeutics

The flavonoid prunin could treat enterovirus A71 infection

DISEASE CATEGORY: Infectious disease INDICATION: Enterovirus The plant pigment prunin could treat infections by enterovirus A71 strains that cause hand, foot and mouth disease, in which a subset of patients develop paralysis. In cell-based infection...
BC Extra | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

A*STAR spinout Lucence raises $20M  IHH led a $20 million series A round for Lucence, a blood-based cancer diagnostics company spun out of Singapore’s Agency for Science, Technology and Research (A*STAR) in 2016. The company...
BC Innovations | Nov 18, 2019
Distillery Therapeutics

Tyrosine kinase inhibitors for the treatment of pemphigus

DISEASE CATEGORY: Autoimmune disease INDICATION: Pemphigus Tyrosine kinase inhibitors including the dual BCR-ABL/c-Kit inhibitor imatinib could treat pemphigus, an autoimmune blistering disorder. Pemphigus is caused by antibodies against the keratinocyte adhesion molecule DSG3. Imatinib reduced...
BC Innovations | Sep 19, 2019
Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 2Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
BC Innovations | Aug 29, 2019
Distillery Techniques

STAT3-based gene signature to predict response to glioblastoma targeted therapy

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling A STAT3-based gene expression signature could identify glioblastoma multiforme (GBM) patients that will respond to STAT3 inhibitors as monotherapies or in combination with IGF1R (insulin-like growth factor-1 receptor; CD221)...
BC Extra | Jul 12, 2019
Financial News

July 11 Financial Quick Takes: Illumina tumbles on revenue miss; plus PureTech, Horizon and more

Illumina falls after revenue miss  Illumina Inc. (NASDAQ:ILMN) was off $58.66 (16%) to $305 in after-hours trading after reporting preliminary 2Q19 revenues of $835 million, barely topping its $830 million revenues in the prior year’s...
BC Extra | Jun 14, 2019
Preclinical News

June 13 Preclinical Quick Takes: A*STAR's mAb against tumor-displayed antigen; plus Columbia, Genentech and more

A*STAR targets externalized antigen to kill tumor cells   The Agency for Science Technology and Research has licensed PTP4A3-targeting cancer therapy PRL3-zumab to spinout company Intra-Immu SG Pte Ltd. (Singapore). A*STAR and colleagues reported in...
BC Innovations | May 20, 2019
Distillery Therapeutics

MAT2A identified as a target in solid and liquid cancers

DISEASE CATEGORY: Cancer INDICATION: Lung; leukemia; lymphoma; solid tumors Cell and mouse studies suggest inhibiting MAT2A could help treat lung and other solid and liquid cancers. In a panel of human cancer cell lines, including...
Items per page:
1 - 10 of 155